Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Nurix Therapeutics Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 examiners across 3 art units, creating a distributed prosecution workload with multiple technical examination settings. Counsel should coordinate claim positions across the portfolio while preserving responses tailored to each assignment.
CHEN, PO-CHIH is the busiest examiner, with 1 pending matter. The absence of a larger concentration in the identified examiner workload means that portfolio management should emphasize cross-matter consistency and technical issue tracking rather than a single-examiner strategy.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| CHEN, PO-CHIH | 1 | 74.3% | +14.7% |
| LEESER, ERICH A | 1 | 81.9% | +13.3% |
| GIERE, REBECCA M | 1 | 73.7% | +32.3% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.1% | +41.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18579114 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY | LEESER, ERICH A | 35d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17775265 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | HEITMEIER, KENDALL NICOLE | 39d |
| 18708175 | TOLL-LIKE RECEPTOR THERAPY COMBINATIONS WITH CBL-B INHIBITOR COMPOUNDS | SHIAO, REI TSANG | — |
| 18290920 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | CHEN, PO-CHIH | — |
| 18302603 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | GIERE, REBECCA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18213177 | COMBINATION THERAPIES WITH CBL-B INHIBITOR COMPOUNDS AND ANTIEMETIC AGENTS | WELLS, LAUREN QUINLAN | 14d |
| 18579114 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY | LEESER, ERICH A | 35d |
| 17775265 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | HEITMEIER, KENDALL NICOLE | 39d |
| 18290920 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | CHEN, PO-CHIH | — |
| 18302603 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | GIERE, REBECCA M | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1622 | 2 |
| 1691 | 1 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18708175 | TOLL-LIKE RECEPTOR THERAPY COMBINATIONS WITH CBL-B INHIBITOR COMPOUNDS | SHIAO, REI TSANG | 1691 | §103§112 | Final Rejection | — | Pending | May 07, 2024 |
| 18290920 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | CHEN, PO-CHIH | 1621 | §103§112Other | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18579114 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY | LEESER, ERICH A | 1622 | §103 | Final Rejection | 35d | Pending | Jan 12, 2024 |
| 18302603 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | GIERE, REBECCA M | 1677 | §101§112 | Non-Final OA | — | Pending | Jul 24, 2023 |
| 18213177 | COMBINATION THERAPIES WITH CBL-B INHIBITOR COMPOUNDS AND ANTIEMETIC AGENTS | WELLS, LAUREN QUINLAN | 1622 | §103§112DP | Non-Final OA | 14d | Pending | Jun 22, 2023 |
| 17775265 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | HEITMEIER, KENDALL NICOLE | 1621 | §103§112 | Non-Final OA | 39d | Pending | May 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNurix Therapeutics Inc. has 6 pending office actions as of October 2026, spread across 4 art units and 6 examiners.
Rei Tsang Shiao has the most, with 1 of Nurix Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
